Meningococcal disease affects 1 in 100,000 people in the US. Disease commonly occurs in children under 1 and adolescents. About 10-15% of meningitis cases result in death. Bacteria can spread through close contact and intimate relationships
Menactra prevents meningococcal infections in serogroups A, C, W, and Y. Vaccine helps develop immunity to meningitis. Approved for ages 9 months to 55 years. Not effective against active meningococcal infections
SRMA is an immune-mediated inflammatory disease affecting leptomeninges and arteries. Most common in dogs 6-18 months, affecting Boxers, Beagles, Bernese, and Weimaraners. Characterized by severe cervical pain, lethargy, and fever. CSF shows neutrophilic pleocytosis with over 80% non-degenerate cells. MRI often normal or mildly abnormal, CSF analysis preferred for diagnosis
Prescription-only meningococcal vaccine containing five serogroups. Contains CRM197 protein conjugated to meningococcal oligosaccharides. Available as powder and solution for injection
Menveo is a vaccine containing parts of Neisseria meningitidis bacteria. Available as powder and solution for injection. Protects against invasive disease in adults and children from age two